ACM
ASMB icon

ADAR1 Capital Management’s Assembly Biosciences ASMB Stock Holding History

ADAR1 Capital Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562K Buy
20,447
+500
+3% +$13.6K 0.03% 203
2026
Q1 		$554K Buy
19,947
+200
+1% +$5.71K 0.03% 198
2025
Q4 		$672K Buy
19,747
+800
+4% +$25.8K 0.05% 169
2025
Q3 		$485K Buy
+18,947
New +$416K 0.05% 139

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ADAR1 Capital Management's ASMB Position: Q2 2026 in Review

ADAR1 Capital Management increased its Assembly Biosciences (ASMB) stake by 2.5% in Q2 2026, buying an estimated $13.6K and bringing the position to 20,447 shares worth $562K. The position accounts for 0.03% of the portfolio, ranked #203.

ADAR1 Capital Management first reported a position in ASMB in Q3 2025 and has held it in 4 quarters since. The position peaked at $672K in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • ADAR1 Capital Management held 20,447 shares of Assembly Biosciences worth $562K as of Q2 2026.
  • ADAR1 Capital Management bought 500 Assembly Biosciences shares in Q2 2026, an estimated $13.6K.
  • Assembly Biosciences made up 0.03% of ADAR1 Capital Management's portfolio in Q2 2026, its #203 holding.
  • ADAR1 Capital Management first reported a position in Assembly Biosciences in Q3 2025 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Assembly Biosciences position peaked at $672K in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.